Poolbeg Pharma (POLB) announced its audited results for the period ended 31 December 2021. The company said it has grown and diversified its portfolio of products and platforms targeting a
Poolbeg Pharma (POLB) announced its audited results for the period ended 31 December 2021. The company said it has grown and diversified its portfolio of products and platforms targeting a
Zak Mir takes a charting perspective on some of the most followed London small caps. Today’s selection includes Audioboom, Beowulf, Canadian, Europa, Egdon, Eve, Genedrive, Kibo, Mosman, Mast, Powerhouse, Synairgen,
Zak Mir previews the best looking small-cap charts for 2022. Today’s selection includes Audioboom, Bidstack, Emmerson, GSTechnologies, Cadence, Marechale, Omega, Pires, Quantum, Synairgen.
Zak Mir takes a charting perspective to some of the most followed small caps on the London market. Today’s selection includes Argo, Cloudbreak, Cornish, Eurasia, Eve, Kodal, Novacyt, Synairgen, Sound,
Zak Mir takes a technical perspective on some of the most followed small caps via the charts of the FTSE 100 and Bitcoin. Today’s stocks include Agronomics, Dev Clever, EQTEC,
Zak Mir takes a technical perspective on some of the most followed small caps on the London market. Today’s selection includes Braveheart, Genedrive, MyHealthChecked, Novacyt, Nanosynth, Scancell, Sareum, Synairgen and
Zak Mir takes a technical perspective on some of the most followed stocks on the London market. Today’s selection includes Caerus, Emmerson, Gulf, Getech, Mode, Synairgen, Tlou, Velocys, Verditek, Zephyr.
Zak Mir takes a technical perspective on some of the most followed stocks on the London market. Today’s selection includes Allergy, Amigo, Kefi, Longboat, Oracle, Oriole, Quantum, Synairgen, Starcom, Tower,
Zak Mir takes a charting perspective on some of the most followed stocks on the London market. Today’s selection includes Avacta, Bidstack, CloudCoco, Cyba, Centrica, Mkango, Nostra Terra, Pensana, Reabold,
There were a couple of overnight broker notes and targets to chew on amongst a couple of the more high profile private investor stocks.
Synairgen announces its inhaled interferon beta (SNG001) is advancing to Phase 3 of the NIH-sponsored
There was further momentum for Xtract Resources (XTR) as it said approval has been received from the Resources Regulator in New South Wales , for a further 13 drill holes